| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Lewis Earl serves as a Director at TGEN and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 37 buys and 1 sell. Those positions are worth an estimated $2.5M at current prices.
Historically, Lewis Earl's trades have earned a middling insider score of 62/100 across 23 rated trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of +16.0%.
The biggest single holding is TGEN (~$2.5M) as Director. Net of sales, the recent Form 4 record there shows accumulation of 319,546 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 17, 2021 | TGEN Tecogen Inc. | Director | Buy | 15,000 | $1.86 | $27,900.00 | +6.0% | -20.7% | -37.0% | |
| Jun 8, 2020 | TGEN Tecogen Inc. | Director | Buy | 11,711 | $0.82 | $9,603.02 | +11.7% | - | - | |
| May 25, 2017 | HBIO Harvard Bioscience Inc | Director | Buy | 12,238 | $2.35 | $28,764.54 | +2.7% | - | - | |
| May 24, 2017 | HBIO Harvard Bioscience Inc | Director | Buy | 10,000 | $2.38 | $23,800.00 | +2.4% | - | - | |
| Dec 6, 2016 | HBIO Harvard Bioscience Inc | Director | Sell | 23,088 | $2.42 | $55,872.96 | -5.6% | - | - | |
| Dec 2, 2015 | HBIO Harvard Bioscience Inc | Director | Buy | 27,221 | $3.28 | $89,284.88 | +7.5% | - | - |